Poster presented at EASL 2025 -Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis

Noureddin, Mazen; González Maldonado, Sandra; Neff, Guy; J Lawitz, Eric; Bugianesi, Elisabetta; Anstee, Quentin; Newsome, Philip N; Ratziu, Vlad; Hosseini-Tabatabaei, Azadeh; Schattenberg, Joern; Alkhouri, Naim; Younes, Ramy; Sanyal, Arun J.; Schoelch, Corinna

doi:10.60915/Boehringer-figshare.29070158.v1

Poster presented at EASL 2025 -Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis

poster

posted on 2025-05-15, 11:00 authored by Mazen Noureddin, Sandra González Maldonado, Guy Neff, Eric J Lawitz, Elisabetta Bugianesi, Quentin Anstee, Philip N Newsome, Vlad Ratziu, Azadeh Hosseini-Tabatabaei, Joern Schattenberg, Naim Alkhouri, Ramy Younes, Arun J. Sanyal, Corinna Schoelch

This poster was presented at EASL 2025